Summary
BeOne Medicines Ltd. (ONC), in its Form 8-K filed November 25, 2019, announced the presentation of preliminary clinical data for its investigational anti-PD-1 antibody, tislelizumab. The data pertains to a Phase 2 trial evaluating tislelizumab in combination with chemotherapy for patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC). This information was shared via a press release on November 23, 2019, and presented at the European Society for Medical Oncology (ESMO) Asia 2019 Congress.
Key Highlights
- 1Presentation of preliminary Phase 2 clinical data for tislelizumab.
- 2Tislelizumab is an investigational anti-PD-1 antibody.
- 3Trial focuses on combination therapy of tislelizumab and chemotherapy.
- 4Target patient populations include gastric/G/GEJ adenocarcinoma and ESCC.
- 5Data was presented at the ESMO Asia 2019 Congress.
- 6Press release announcing the data is filed as an exhibit.
Frequently Asked Questions
The primary focus of this 8-K filing is the announcement of preliminary clinical data from a Phase 2 trial of BeOne Medicines' anti-PD-1 antibody, tislelizumab, in combination with chemotherapy for specific types of upper gastrointestinal cancers.
Tislelizumab is an investigational anti-PD-1 antibody being developed by BeOne Medicines.
The Phase 2 trial investigated tislelizumab in combination with chemotherapy for patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC).
The preliminary clinical data was presented at the European Society for Medical Oncology (ESMO) Asia 2019 Congress in Singapore.